Logo image
Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
Journal article   Peer reviewed

Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma

S.C-H Kao, K. Griggs, K. Lee, N. Armstrong, S. Clarke, J. Vardy, N. van Zandwijk, J. Burn, B.C. McCaughan, D.W. Henderson, …
Pathology, Vol.43(4), pp.313-317
2011
url
Link to Published Version *Subscription may be requiredView

Abstract

AIMS: We previously established the use of a minimal panel of antibodies as sufficient to diagnose most epithelial malignant mesothelioma (MPM). We aimed to validate this approach and investigate the utility of a D2-40 antibody. METHODS: A series of 80 MPM patients selected for surgery and 21 consecutive patients with pleural metastatic carcinoma were included. A minimal panel of antibodies, consisting of calretinin, BG8 and CD15, and D2-40 was investigated. RESULTS: There were 61 epithelial and 19 biphasic MPM as well as 12 metastatic lung, six breast (5 ductal adenocarcinomas, 1 mixed ductal/lobular adenocarcinoma), two serous papillary ovarian carcinomas and one moderately differentiated colorectal adenocarcinoma. The sensitivity of positive calretinin labelling to confirm the diagnosis of MPM was 97.5%, while the 'diagnostic sensitivities' of lack of labelling for BG8 and CD15 were 91.3% and 97.5%, respectively. The use of calretinin, BG8 and CD15 resulted in correct classification in 97.5% of all MPMs. All MPM cases investigated showed at least focal positive D2-40 labelling. CONCLUSIONS: We have validated the usefulness of a minimal panel of antibodies with calretinin, BG8 and CD15 as the initial step to the diagnosis of MPM. D2-40 emerged as a helpful diagnostic tool for cases where our initial approach failed to conclusively diagnose MPM.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.297 Asbestos & Mesothelioma
1.297.780 Asbestos-Mesothelioma Link
Web Of Science research areas
Pathology
ESI research areas
Clinical Medicine
Logo image